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Summary: We report that SARS-CoV-2 spike mutations L452R and E484Q (as observed in B.1.617.1) 
each confer modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies, and the 























The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have 
been fears that two key mutations seen in the receptor binding domain L452R and E484Q would 
have additive effects on evasion of neutralising antibodies. We report that spike bearing L452R and 
E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies 
following either first or second dose. The effect is similar in magnitude to the loss of sensitivity 
conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine elicited 























Global control of the SARS-CoV-2 pandemic has yet to be realised despite availability of highly 
effective vaccines. Emergence of new variants with multiple mutations is likely the result of chronic 
infections within individuals who are immune compromised1. These new variants with antibody 
escape mutations has coincided with vaccine scale up, potentially threatening their success in 
controlling the pandemic2, 3.   
 
India experienced a wave of infections in mid 2020 that was controlled by a nationwide lockdown. 
Since easing of restrictions, India has seen expansion in cases of COVID-19 since March 2021. The 
B.1.617 variant emerged in the state of Maharashtra in late 2020/early 2021 and has spread 
throughout India and to at least 60 countries. It was labelled initially as a ‘double mutant‘ since two 
of the mutations L452R and E484Q were matched to an in-house screening database for mutations 
leading to probable evasion of antibodies and/or being linked to increased transmissibility. 
 
L452R and E484Q are located in the critical receptor binding domain that interacts with ACE24. 
L452R was observed in the ‘Epsilon Variant’ B.1.429 and is associated with increase in viral load and 
around 20% increased transmissibility 5. It was also associated with increased ACE2 binding, 
increased infectivity6 and 3-6 fold loss of neutralisation sensitivity to vaccine elicited sera in 
experiments with pseudotyped virus (PV) particles6, 7. Little is known about E484Q, though E484K is a 
defining feature of two VOCs, B.1.351 and P.1, and is found alongside K417N/T as well as N501Y in 























All sequences excluding low-quality sequences (>5% N regions) with the L452R mutation were 
downloaded from https://gisaid.org on the 4th May 2021 and manually aligned to reference strain 
MN908947.3 with mafft v4.475 using the --keeplength --addfragments option. Sequences were de-
duplicated using bbtools dedupe.sh. A random subset of 400 global sequences (excluding USA), and 
100 USA sequences were then selected with seqtk and concatenated. Sequence lineages were 
assigned to all sequences with pangolin v2.4 (https://github.com/cov-lineages/pangolin) and 
pangolearn (04/05/2021).  
 
Phylogenies were then inferred using maximum-likelihood in IQTREE v2.1.3 9 using a GTR+R6 model 
and the -fast option. Mutations of interest were determined using a local instance of nextclade-cli 
v0.14.2 (https://github.com/nextstrain/nextclade). The inferred phylogeny was annotated in R v4.04 
using ggtree v2.2.4 and rooted on the SARS-CoV-2 reference sequence, and nodes arranged in 
descending order. Major lineages were annotated on the phylogeny, as well as a heatmap indicating 
which mutations of interest were carried by each viral sequence. 
 
Structural Analyses 
The PyMOL Molecular Graphics System v.2.4.0 (https://github.com/schrodinger/pymol-open-
source/releases) was used to map the location of the two RDB mutants L452R and E484Q onto two 
previously published SARS-CoV-2 spike glycoprotein structures. The two structures included a 
closed-conformation spike protein - PDB: 6ZGE and a spike protein in open conformation, bound to 





















Serum samples and ethical approval 
Ethical approval for use of serum samples. Controls with COVID-19 were enrolled to the NIHR 
BioResource Centre Cambridge under ethics review board (17/EE/0025). Protocols involving human 
subjects recruited at Kyoto University, Japan, were reviewed and approved by (approval numbers 
G0697 and G1309). All human subjects provided written informed consent. 
 
Cells 
HEK 293T CRL-3216, Vero CCL-81 were purchased from ATCC and maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and 
100mg/ml streptomycin. All cells were regularly tested and are mycoplasma free.  
 
Pseudotype virus preparation 
Plasmids encoding the spike protein of SARS-CoV-2 with a C terminal 19 amino acid deletion with 
D614G, were used. Mutations were introduced using Quickchange Lightning Site-Directed 
Mutagenesis kit (Agilent) following the manufacturer’s instructions. Viral vectors were prepared by 
transfection of 293T cells by using Fugene HD transfection reagent (Promega). 293T cells were 
transfected with a mixture of 11ul of Fugene HD, 1µg of pCDNAΔ19 spike-HA, 1ug of p8.91 HIV-1 
gag-pol expression vector and 1.5µg of pCSFLW (expressing the firefly luciferase reporter gene with 
the HIV-1 packaging signal). Viral supernatant was collected at 48 and 72h after transfection, filtered 
through 0.45um filter and stored at -80˚C. Infectivity was measured by luciferase detection in target 





















Standardisation of virus input by SYBR Green-based product-enhanced PCR assay (SG-PERT) 
The reverse transcriptase activity of virus preparations was determined by qPCR using a SYBR Green-
based product-enhanced PCR assay (SG-PERT) as previously described11. Briefly, 10-fold dilutions of 
virus supernatant were lysed in a 1:1 ratio in a 2x lysis solution (made up of 40% glycerol v/v 0.25% 
Trition X-100 v/v 100mM KCl, RNase inhibitor 0.8 U/ml, TrisHCL 100mM, buffered to pH7.4) for 10 
minutes at room temperature. 
 
Serum pseudotype neutralisation assay for Pfizer BNT162b2 dose 1 experiments 
Virus neutralisation assays were performed on 293T cell transiently transfected with ACE2 and 
TMPRSS2 using SARS-CoV-2 spike pseudotyped virus expressing luciferase12. Pseudotyped virus was 
incubated with serial dilution of heat inactivated human serum samples or convalescent plasma in 
duplicate for 1h at 37˚C. Virus and cell only controls were also included. Then, freshly trypsinized 
293T ACE2/TMPRSS2 expressing cells were added to each well. Following 48h incubation in a 5% 
CO2 environment at 37°C, the luminescence was measured using Steady-Glo Luciferase assay system 
(Promega). IC50 was calculated in GraphPad Prism v8.0. 
 
Establishment of stable cells for Pfizer dose 2 experiments 
The ACE2-expressing lentiviral plasmid pWPI-ACE2-zeo was generated by replacing the original EGFP 
gene of the lentiviral transfer plasmid pWPI (Pham et al., 2004), with the zeocin-resistant gene, and 
by inserting the ACE2 gene into the region immediately upstream of the internal ribosome entry site. 
Similarly, the TMPRSS2-expressing lentiviral plasmid pWPI-TMPRSS2-neo was created by inserting 





















293T cells (4.4 x 105) were cotransfected with 0.1 μg of pC-VSVg, 0.95 μg of psPAX2-IN/HiBiT (Ozono 
et al., 2021), and 0.95 μg of either pWPI-ACE2-zeo or pWPI-TMPRSS2-neo, using FuGENE 6 
(Promega). Sixteen hours later, the cells were washed with phosphate-buffered saline, and 1 ml of 
fresh complete medium was added. After 24 h, the supernatants were harvested and treated with 
DNase I (Roche) at 37 °C for 30min. The lentivirus levels in viral supernatants were measured by the 
HiBiT assay, as previously described (Ozono et al., 2020). HOS cells (1 x 105) were then transduced 
with the ACE2-expressing lentiviral vector and the TMPRSS2-expressing lentiviral vector at a 
multiplicity of infection of 2. After 48 h, transduced cells were maintained for zeocin (50 μg ml−1; 




We subsampled SARS-CoV-2 sequences containing L452R from GISAID, and inferred a maximum 
likelihood phylogenetic tree (Figure 1A). We annotated the sequences based on the accompanying 
mutations and observed three lineages within B.1.617.  B.1.617.1 has three key spike mutations 
L452R, E484Q and P681R, whereas B.1.617.2 is characterised by L452R, T478K and P681R (cleavage 
site region). There was likely loss of E484Q in B.1.617.2 given that B.1.617.3 also bears E484Q (Figure 
1A), indicating E484Q was present in the ancestral virus. There are multiple other mutations in the 
NTD and S2 regions of B.1.617 lineages. The number of sequenced isolates of B.1.617.1 and 
B.1.617.2 has been steadily increasing in India (Figure 1B), though with the caveat of very low 
sequencing of prevalent cases and heterogeneous sampling across the country.  
 
Spike mutations L452R and E484Q are in the receptor binding domain that not only binds ACE213, 




















combinations of mutations found in B.1.617.1: L452R, E484Q and P681R, using a previously reported 
pseudotyped virus (PV) system. We tested 24 stored sera from first dose (Figure 2B) and 16 sera 
from second dose (Figure 2C) Pfizer BNT162b2 vaccinees against a range of spike mutation bearing 
PV (Figure 2B,C, Supplementary Figure 1B,C). E484Q had a similar impact on reducing neutralisation 
sensitivity as L452R and E484K (3.6-4.5 fold). When E484Q and L452R were combined, there was a 
statistically significant loss of sensitivity as compared to wild type, but the fold change of 5.1 was 
similar to that observed with each mutation individually with absence of evidence for an additive 
effect (Figure 2B, Supplementary Figure 1B). However, as expected, in some sera there was evidence 
for variable neutralising activity against the L452R and E484Q PVs, reflecting differential antibody 
responses between individuals. When we tested second dose sera (Figure 2C, Supplementary Figure 
1C), similar patterns were observed between different viruses although fold changes were lower 
overall, likely due to increased neutralisation breadth and potency following booster vaccination8. 
 
Finally, with the PV system we measured spike mediated entry into target HOS cells endogenously 
expressing ACE2 and TMPRSS2 receptors. The E484K and L452R mutant did not have significantly 
higher entry efficiency compared to single mutants (Figure 2D). We also tested the entry efficiency 
of L452R, E484Q and P681R in a range of target cell lines, either exogenously or endogenously 
expressing SARS-CoV-2 receptors ACE2/TMPRSS2. The spike triple mutant exhibited similar or mildly 




Here we demonstrate three lineages of B.1.617, all bearing the L452R mutation. We report key 




















mutations L452R, E484Q. In vitro, we find modestly reduced sensitivity of the spike protein bearing 
RBD mutations L452R and E484Q to BNT162b2 mRNA vaccine-elicited antibodies that is similar in 
magnitude to the loss of sensitivity conferred by L452R or E484Q alone. P681R did not appear to 
alter the sensitivity to vaccine sera or to alter the entry efficiency conferred by spike protein on 
lentiviral particles. These data demonstrate reduced sensitivity to vaccine elicited neutralising 
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Figure 1. SARS-CoV-2 B.1.617 variant emerging in India A. Maximum-likelihood phylogeny of 
lineages bearing L452R in spike. All sequences with the L452R mutation were downloaded from 
https://gisaid.org and manually aligned to reference strain MN908947.3 with mafft. Sequences were 
de-duplicated and a random subset of 400 global sequences, and 100 USA sequences were then 
selected with seqtk. All sequence lineages were assigned using pangolin v2.4. Major lineages are 
indicated as straight lines adjacent to the heatmap, alongside mutations of current interest. The 
phylogeny was inferred with IQTREE2 v2.1.3. B. The number of B.1617 cases per month in India in 
the first half of 2021.  
 
Figure 2. Entry efficiency and neutralisation sensitivity of B.1.617 mutant pseudotyped viruses 
following mRNA vaccination A. Surface representation of the spike protein in open formation with 
neutralising antibody H4 (pink spheres, PDB: 7L58, Rapp et al, 2021) bound to one monomer of the 
spike protein. Residues L452 and E484 are indicated with red and green sphere, respectively. Ribbon 
representation of the interaction between the neutralising antibody H4 and the RBD of a spike 
monomer. Neutralisation by B. first dose and C. second dose mRNA vaccine-elicited sera against 
wild type and mutant SARS-CoV-2 spike pseudotyped viruses. Reciprocal geometric mean titre 
(GMT) shown with 95% CI. *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001. D. Virus infectivity of 
pseudotyped virus (PV) bearing indicated spike mutations. PV were generated in 293T cells and used 
to infect HOS cells transduced with ACE2 and TMPRSS2. Input virus was normalized for protein 






















Supplementary Figure 1: Neutralisation sensitivity of B.1.617 mutant pseudotyped viruses 
following mRNA vaccination A. Representative neutralisation curves from mRNA first dose vaccine 
sera tested against PV bearing spike mutations observed in B.1.617.1 RBD. Error bars represent 
standard error of mean of technical replicates. Data are representative of two independent 
experiments. Neutralisation by B. first dose and C. second dose mRNA vaccine-elicited sera against 
wild type and mutant SARS-CoV-2 spike pseudotyped viruses. Reciprocal geometric Mean Titre 
(GMT) shown *p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001. D. Reciprocal geometric mean titre 
(GMT) for first and second dose sera against SARS-CoV-2 spike PV with standard error of the mean. 
 
Supplementary Figure 2: Entry efficiency of B.1.617 mutant pseudotyped viruses. Virus infectivity 
of pseudotyped virus (PV) bearing indicated spike mutations. PV were generated in 293T cells, 
filtered and then used to infect a range of target cells. Luciferase was measured 48 hours after 
infection. Input virus inoculum was corrected for genome copy input using SG-PERT. Mean is plotted 
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